Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
24,206.80
(
2.83%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
92.71
(
-8.40%
)
Bitcoin
71,609.61
(
-0.52%
)
News Focus
News Focus
Post# of 3757
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122853
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 683

Sunday, 04/22/2007 12:35:58 AM

Sunday, April 22, 2007 12:35:58 AM

Post# of 3757
Roche’s R1626 HCV polymerase inhibitor has shown unacceptable neutropenia in the existing phase-2 trial (#msg-13986782). As a result, R1626 will have to be tested in a second phase-2 trial using a lower dose.

Source: Roche’s 1Q07 CC

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote